Guidance for switching from off-label antipsychotics to pimavanserin for Parkinson's disease psychosis: an expert consensus.

Authors

• Kevin J Black
• Henry Nasrallah
• Stuart Isaacson
• Mark Stacy
• Rajesh Pahwa
• Charles H Adler
• Gustavo Alva
• Jeffrey W Cooney
• Daniel Kremens
• Matthew A Menza
• Johnathan M Meyer
• Ashwin A Patkar
• Tanya Simuni
• Debbi A Morrissette
• Stephen M Stahl

Publication/Presentation Date

10-1-2019

Volume

24

Issue

5

First Page

574

Last Page

575

ISSN

2165-6509

Published In/Presented At

Black, K. J., Nasrallah, H., Isaacson, S., Stacy, M., Pahwa, R., Adler, C. H., Alva, G., Cooney, J. W., Kremens, D., Menza, M. A., Meyer, J. M., Patkar, A. A., Simuni, T., Morrissette, D. A., & Stahl, S. M. (2019). Guidance for switching from off-label antipsychotics to pimavanserin for Parkinson's disease psychosis: an expert consensus. CNS spectrums, 24(5), 574–575. https://doi.org/10.1017/S1092852919000932

Disciplines

Business Administration, Management, and Operations | Health and Medical Administration | Management Sciences and Quantitative Methods

PubMedID

31182180

Department(s)

Administration and Leadership

Document Type

Article